combination therapy

Exelixis
Biotech

Exelixis’ Cabometyx successor misses primary endpoint in CRC trial

While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.
Angus Liu Jun 22, 2026 3:40pm
dart board miss failure
Favicon Fierce Pharma

Merck's Welireg surprisingly fails in first-line kidney cancer

Apr 21, 2026 10:00am
JNJ
Favicon Fierce Pharma

ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma

Dec 9, 2025 7:30am
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin
Favicon Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am
BioNTech

BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC

Sep 8, 2025 11:00am